Scarica l'app Stockscreener
31.31
3.95%
1.19
Dopo l'orario di chiusura:
31.31
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
The Technical Signals Behind (VTVT) That Institutions Follow - Stock Traders Daily
vTv Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Lowers Earnings Estimates for vTv Therapeutics - MarketBeat
vTv Therapeutics Inc (VTVT) Reports Q2 Loss of $1.05 Per Share -- What Does a GF Score of 26/100 Indicate? - GuruFocus
vTv Therapeutics Inc (VTVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
vTv Therapeutics Inc (VTVT) Stock News Today - TradingKey
vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - Kalkine
vTv Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
vTv Therapeutics (VTVT) Advances Diabetes Treatment Amid High Pr - GuruFocus
VTVT Maintains Buy Rating -- Price Target Lowered to $42.00 by H - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright - MarketBeat
VTv Therapeutics: Q2 Earnings Snapshot - marketscreener.com
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
VTV THERAPEUTICS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $42 FROM $45 - Bitget
VTVT Q2'26 Earnings: revenue estimate is 333.33K USD - TradingView
vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Precision Trading with Vtv Therapeutics Inc. (VTVT) Risk Zones - Stock Traders Daily
vTv Therapeutics (VTVT) Edges Down 1% to $32.35, Holding Gains Above Key SupportMotive Wave - dars.gov.et
vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving AverageHere's What Happened - marketbeat.com
vTv Therapeutics Inc. Revenue Breakdown – NASDAQ:VTVT - TradingView
vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
vTv Therapeutics (VTVT): Millennium entities disclose 6.9% ownership of Class A shares - Stock Titan
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
vTv Therapeutics Grants Employees Options With 4-Year Vesting - Stock Titan
vTv Therapeutics Inc (VTVT) Cash Flow - TradingKey
vTv Therapeutics Inc (VTVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
vTv Therapeutics Inc (VTVT) Balance Sheet - TradingKey
vTv Therapeutics Inc (VTVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VTVT|vTv Therapeutics Inc|Price:31.030|Chg%:+0.300 - TradingKey
vTv Therapeutics Inc (VTVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
vTv Therapeutics Inc (VTVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
vTv Therapeutics (VTVT) Fades 2.9% as Cautious Trading Prevails Near Key ResistanceWeak Sell Signals - dars.gov.et
vTv Therapeutics, Inc. Class A Revenue Breakdown – SWB:5VT0 - TradingView
TradingKey - TradingKey
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Technical Reactions to VTVT Trends in Macro Strategies - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT) - The Globe and Mail
VTVT Maintains Buy Rating by BTIG -- Price Target Raised to $57. - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
MSN Money - MSN
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Recurring Items, Stock DeclinesRevenue Guidance Range - DonanımHaber
vTv Therapeutics lures two employees with 12,500 stock options - Stock Titan
vTv Therapeutics Shareholders Approve Directors, Question Executive Pay - The Globe and Mail
Trading the Move, Not the Narrative: (VTVT) Edition - Stock Traders Daily
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating - Investing.com
Enterprise value to EBITDA forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds - Stock Titan
Form 4 vTv Therapeutics Inc For: 29 June By Investing.com - Investing.com India
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
vTv Therapeutics (VTVT) director granted 6,000 stock options at $35.08 - Stock Titan
Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant - Stock Titan
Director at vTv Therapeutics (VTVT) receives 6,000 stock options grant - Stock Titan
Director Fahed Al-Marzooqi (VTVT) granted 6,000 vTv Therapeutics stock options - Stock Titan
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):